Therefore, targeting PIKfyve may not just augment ICB in prostate cancer (30), but also improve response to other CD8+ T cell–dependent immunotherapies, such as adoptive cell therapies and therapeutic vaccines, across various cancer types. This evidence concerns the gene CD8A and prostate cancer.